%0 Journal Article %T Tumor Immunotargeting Using Innovative Radionuclides %+ Centre de Recherche en Cancérologie Nantes-Angers (CRCNA) %+ Département de Médecine Nucléaire [CHU Nantes] %+ Département de Médecine Nucléaire [ICO-Site Gauducheau, Saint-Herblain] %+ Département de Radiologie [CHU Nantes] %+ Animaux modèles pour la recherche en oncologie comparée (AMaROC) %+ Département de Physique [Nantes] (GIP Arronax) %A Kraeber-Bodéré, Françoise %A Rousseau, Caroline %A Bodet-Milin, Caroline %A Mathieu, Cédric %A Guérard, François %A Frampas, Eric %A Carlier, Thomas %A Chouin, Nicolas %A Haddad, Ferid %A Chatal, Jean-François %A Faivre-Chauvet, Alain %A Chérel, Michel %A Barbet, Jacques %Z This work has been supported in part by a grant from the French National Agency for Research, called “Investissements d’Avenir” no. ANR-11-LABX-0018-01. %< avec comité de lecture %@ 1661-6596 %J International Journal of Molecular Sciences %I MDPI %V 16 %N 2 %P 3932 - 3954 %8 2015-02 %D 2015 %R 10.3390/ijms16023932 %M 25679452 %K alpha particle-emitting radionuclides %K innovative radionuclides %K alpha-immunotherapy %K radioimmunotherapy %K immuno-PET %Z Life Sciences [q-bio]/CancerJournal articles %X This paper reviews some aspects and recent developments in the use of antibodies to target radionuclides for tumor imaging and therapy. While radiolabeled antibodies have been considered for many years in this context, only a few have reached the level of routine clinical use. However, alternative radionuclides, with more appropriate physical properties, such as lutetium-177 or copper-67, as well as alpha-emitting radionuclides, including astatine-211, bismuth-213, actinium-225, and others are currently reviving hopes in cancer treatments, both in hematological diseases and solid tumors. At the same time, PET imaging, with short-lived radionuclides, such as gallium-68, fluorine-18 or copper-64, or long half-life ones, particularly iodine-124 and zirconium-89 now offers new perspectives in immuno-specific phenotype tumor imaging. New antibody analogues and pretargeting strategies have also considerably improved the performances of tumor immunotargeting and completely renewed the interest in these approaches for imaging and therapy by providing theranostics, companion diagnostics and news tools to make personalized medicine a reality. %G English %2 https://www.hal.inserm.fr/inserm-01818715/document %2 https://www.hal.inserm.fr/inserm-01818715/file/ijms-16-03932.pdf %L inserm-01818715 %U https://www.hal.inserm.fr/inserm-01818715 %~ INSERM %~ UNIV-NANTES %~ MINES-NANTES %~ SUBATECH %~ CNRS %~ LORIA2 %~ UNAM %~ CRCNA %~ AGREENIUM %~ IMTA_SUBATECH %~ IMT-ATLANTIQUE %~ SUBATECH-PRISMA %~ ANR %~ DEESSE